Roivant Sciences Ltd. (NASDAQ:ROIV - Get Free Report) COO Eric Venker sold 100,000 shares of the firm's stock in a transaction that occurred on Friday, June 20th. The shares were sold at an average price of $11.45, for a total value of $1,145,000.00. Following the completion of the transaction, the chief operating officer now owns 1,462,223 shares of the company's stock, valued at approximately $16,742,453.35. This represents a 6.40% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.
Eric Venker also recently made the following trade(s):
- On Tuesday, June 3rd, Eric Venker sold 566,278 shares of Roivant Sciences stock. The shares were sold at an average price of $11.22, for a total transaction of $6,353,639.16.
- On Monday, June 2nd, Eric Venker sold 433,722 shares of Roivant Sciences stock. The shares were sold at an average price of $11.07, for a total transaction of $4,801,302.54.
- On Tuesday, May 20th, Eric Venker sold 100,000 shares of Roivant Sciences stock. The stock was sold at an average price of $10.95, for a total value of $1,095,000.00.
- On Monday, April 21st, Eric Venker sold 100,000 shares of Roivant Sciences stock. The shares were sold at an average price of $10.22, for a total value of $1,022,000.00.
Roivant Sciences Stock Performance
Shares of ROIV stock traded down $0.21 during mid-day trading on Friday, hitting $11.39. The company's stock had a trading volume of 11,069,902 shares, compared to its average volume of 5,881,149. The company has a market cap of $7.74 billion, a PE ratio of -45.56 and a beta of 1.16. The company's fifty day simple moving average is $11.08 and its 200-day simple moving average is $10.93. Roivant Sciences Ltd. has a 52 week low of $8.73 and a 52 week high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last released its quarterly earnings data on Thursday, May 29th. The company reported ($0.31) earnings per share for the quarter, missing the consensus estimate of ($0.16) by ($0.15). The company had revenue of $7.57 million during the quarter, compared to the consensus estimate of $62.17 million. Roivant Sciences had a negative net margin of 225.71% and a negative return on equity of 14.76%. During the same quarter in the prior year, the firm earned ($0.23) EPS. On average, equities analysts anticipate that Roivant Sciences Ltd. will post -0.92 earnings per share for the current year.
Wall Street Analyst Weigh In
Several equities analysts recently commented on ROIV shares. HC Wainwright reissued a "buy" rating and issued a $18.00 price objective on shares of Roivant Sciences in a research note on Wednesday, June 18th. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a research report on Tuesday, March 4th.
Get Our Latest Stock Analysis on ROIV
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in ROIV. Thompson Siegel & Walmsley LLC raised its position in shares of Roivant Sciences by 10.1% during the fourth quarter. Thompson Siegel & Walmsley LLC now owns 565,337 shares of the company's stock worth $6,688,000 after purchasing an additional 51,705 shares during the period. Russell Investments Group Ltd. boosted its position in shares of Roivant Sciences by 478.6% during the fourth quarter. Russell Investments Group Ltd. now owns 2,355 shares of the company's stock valued at $28,000 after buying an additional 1,948 shares during the last quarter. Raymond James Financial Inc. bought a new stake in Roivant Sciences during the fourth quarter worth $995,000. Monimus Capital Management LP purchased a new stake in Roivant Sciences in the 4th quarter valued at $1,621,000. Finally, Bank of Montreal Can lifted its stake in Roivant Sciences by 20.2% during the 4th quarter. Bank of Montreal Can now owns 48,026 shares of the company's stock valued at $568,000 after acquiring an additional 8,084 shares in the last quarter. 64.76% of the stock is owned by institutional investors and hedge funds.
Roivant Sciences Company Profile
(
Get Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Further Reading

Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.